Aberdeen Group plc Grows Stock Position in Xencor, Inc. $XNCR

Key Points

• Aberdeen Group plc increased its position in Xencor, Inc. by 48.2%, owning approximately 558,810 shares valued at $4,392,000 as of their latest SEC filing.
• Xencor reported a notable revenue increase of 82.4% year-over-year, reaching $43.61 million, and surpassed earnings expectations with EPS of ($0.41).
• Analyst ratings for Xencor show a mix of sentiments, with one strong buy, seven buys, and two sells, resulting in a moderate buy rating with an average target price of $24.22.

Aberdeen Group plc grew its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 48.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 558,810 shares of the biopharmaceutical company's stock after purchasing an additional 181,698 shares during the quarter. Aberdeen Group plc owned approximately 0.79% of Xencor worth $4,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Wyoming purchased a new stake in shares of Xencor during the 1st quarter valued at about $34,000. CWM LLC increased its position in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of Xencor during the 1st quarter valued at about $56,000. GAMMA Investing LLC increased its position in shares of Xencor by 348.5% during the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company's stock valued at $102,000 after purchasing an additional 7,482 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in Xencor by 23.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 1,896 shares in the last quarter.

Xencor Price Performance

XNCR stock opened at $14.95 on Friday. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $27.24. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.23 and a beta of 0.96. The business has a 50 day simple moving average of $9.68 and a two-hundred day simple moving average of $9.13.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $43.61 million during the quarter, compared to the consensus estimate of $22.59 million. During the same period in the prior year, the company posted ($1.07) EPS. The firm's revenue for the quarter was up 82.4% compared to the same quarter last year. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada reduced their target price on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, August 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of Xencor in a report on Tuesday. Cantor Fitzgerald raised shares of Xencor to a "strong-buy" rating in a report on Wednesday, October 8th. Wells Fargo & Company reduced their target price on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Barclays assumed coverage on shares of Xencor in a report on Wednesday, September 17th. They issued an "underweight" rating and a $6.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $24.22.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.